Cosmo Pharmaceuticals NV 2020 AR2
The report highlights Cosmo Pharmaceuticals' financial and operational performance for the fiscal year 2020. The company achieved an operating profit of EUR 6.9 million and a positive cash flow from operating activities of EUR 10.1 million, recovering from an operating loss in 2019. Key milestones included the European approval of Methylene Blue MMX, FDA approval of BYFAVO, and positive clinical results for the GI Genius intelligent endoscopy device. Cosmo also expanded its pipeline through strategic licensing agreements, including partnerships with Acacia Pharma and China Medical System Holdings.
Company: Cosmo Pharmaceuticals NV
Sector: Manufacturing
Country: Ireland
Year: 2020
Type: AR2
Pages: 174
Back to company
Cosmo Pharmaceuticals NV
Annual Report & Accounts
The report highlights Cosmo Pharmaceuticals' financial and operational performance for the fiscal year 2020. The company achieved an operating profit of EUR 6.9 million and a positive cash flow from operating activities of EUR 10.1 million, recovering from an operating loss in 2019. Key milestones included the European approval of Methylene Blue MMX, FDA approval of BYFAVO, and positive clinical results for the GI Genius intelligent endoscopy device. Cosmo also expanded its pipeline through strategic licensing agreements, including partnerships with Acacia Pharma and China Medical System Holdings.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees